OpenURL Connection Search

Select item for more details and to access through your institution.

POLATUZUMAB, BENDAMUSTINE & RITUXIMAB EFFICACY IN RELAPSED/REFRACTORY TRIAL‐INELIGIBLE LARGE B CELL LYMPHOMA PATIENTS: AN AUSTRALIAN LYMPHOMA REGISTRY (LARDR) STUDY.
Published in:
Hematological Oncology, 2023, v. 41, p. 718, doi. 10.1002/hon.3165_572
By:
- Shaw, B.;
- Chung, E.;
- Wellard, C.;
- Yoo, E.;
- Bennett, R.;
- Birks, C.;
- Johnston, A.;
- Cheah, C.;
- Hamad, N.;
- Simpson, J.;
- Barraclough, A.;
- Ku, M.;
- Viiala, N.;
- Ratnasingam, S.;
- Armytage, T.;
- Cochrane, T.;
- Chong, G.;
- Lee, D.;
- Manos, K.;
- Keane, C.
Publication type:
Article
Glofitamab plus R‐CHOP or polatuzumab vedotin‐R‐CHP is deliverable with high overall response in patients ≤65 years of age with high‐risk DLBCL: Interim analysis of COALITION.
Published in:
Hematological Oncology, 2023, v. 41, p. 421, doi. 10.1002/hon.3164_309
By:
- Minson, A.;
- Verner, E.;
- Giri, P.;
- Wong, S. M.;
- Ratnasingam, S.;
- Butler, J.;
- Janowski, W.;
- Ku, M.;
- Cheah, C. Y.;
- Hertzberg, M.;
- Herbert, K.;
- Hamad, N.;
- Yannakou, C. K.;
- Neeson, P.;
- Saghebi, J.;
- Blombery, P.;
- Robertson, M.;
- Lau, L. S.;
- Xie, J.;
- Seymour, J. F.
Publication type:
Article
BRUTON'S TYROSINE KINASE (BTK) INHIBITOR BGB-3111 DEMONSTRATES HIGH VERY GOOD PARTIAL RESPONSE (VGPR) RATE IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA (WM).
Published in:
Hematological Oncology, 2017, v. 35, p. 70, doi. 10.1002/hon.2437_58
By:
- Trotman, J.;
- Opat, S.;
- Marlton, P.;
- Gottlieb, D.;
- Simpson, D.;
- Cull, G.;
- Ritchie, D.;
- Verner, E.;
- Ratnasingam, S.;
- Anderson, M.;
- Wood, P.;
- Wang, L.;
- Xue, L.;
- Hedrick, E.;
- Huang, J.;
- Hilger, J.;
- Seymour, J.F.;
- Roberts, A.W.;
- Tam, C.S.
Publication type:
Article
HIGH OVERALL RESPONSE RATE WITH THE BTK INHIBITOR BGB-3111 IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA: AN UPDATE ON SAFETY AND ACTIVITY.
Published in:
Hematological Oncology, 2017, v. 35, p. 234, doi. 10.1002/hon.2438_97
By:
- Seymour, J.F.;
- Opat, S.;
- Cull, G.;
- Trotman, J.;
- Gottlieb, D.;
- Simpson, D.;
- Marlton, P.;
- Anderson, M.;
- Ku, M.;
- Ritchie, D.S.;
- Ratnasingam, S.;
- Augustson, B.;
- Kim, W.;
- Wang, L.;
- Xue, L.;
- Hilger, J.;
- Huang, J.;
- Hedrick, E.;
- Roberts, A.W.;
- Tam, C.S.
Publication type:
Article

Found: 4

POLATUZUMAB, BENDAMUSTINE & RITUXIMAB EFFICACY IN RELAPSED/REFRACTORY TRIAL‐INELIGIBLE LARGE B CELL LYMPHOMA PATIENTS: AN AUSTRALIAN LYMPHOMA REGISTRY (LARDR) STUDY.

Glofitamab plus R‐CHOP or polatuzumab vedotin‐R‐CHP is deliverable with high overall response in patients ≤65 years of age with high‐risk DLBCL: Interim analysis of COALITION.

BRUTON'S TYROSINE KINASE (BTK) INHIBITOR BGB-3111 DEMONSTRATES HIGH VERY GOOD PARTIAL RESPONSE (VGPR) RATE IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA (WM).

HIGH OVERALL RESPONSE RATE WITH THE BTK INHIBITOR BGB-3111 IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA: AN UPDATE ON SAFETY AND ACTIVITY.